Education
About Us
Working with TipRanks
Follow Us
Cytek Biosciences (CTKB)
NASDAQ:CTKB
Total Valuation
Cytek Biosciences has a market cap or net worth of $306.52M. The enterprise value is $291.53M.
Market Cap$306.52M
Enterprise Value$291.53M
Share Statistics
Cytek Biosciences has 126,659,195 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding126,659,195
Owned by Insiders9.04%
Owned by Institutions16.20%
Financial Efficiency
Cytek Biosciences’s return on equity (ROE) is -0.02 and return on invested capital (ROIC) is -5.02%.
Return on Equity (ROE)-0.02
Return on Assets (ROA)-0.01
Return on Invested Capital (ROIC)-5.02%
Return on Capital Employed (ROCE)-0.05
Revenue Per Employee302.34K
Profits Per Employee-9.08K
Employee Count663
Asset Turnover0.40
Inventory Turnover2.04
Valuation Ratios
The current PE Ratio of Cytek Biosciences is -140.81. Cytek Biosciences’s PEG ratio is -1.54.
PE Ratio-140.81
PS Ratio0.00
PB Ratio0.95
Price to Fair Value2.14
Price to FCF17.09
Price to Operating Cash Flow14.89
PEG Ratio-1.54
Income Statement
In the last 12 months, Cytek Biosciences had revenue of 200.45M and earned -6.02M in profits. Earnings per share was -0.05.
Revenue200.45M
Gross Profit111.11M
Operating Income-20.52M
Pretax Income-5.70M
Net Income-6.02M
EBITDA-10.03M
Earnings Per Share (EPS)-0.05
Cash Flow
In the last 12 months, operating cash flow was 25.38M and capital expenditures -3.53M, giving a free cash flow of 21.84M billion.
Operating Cash Flow25.38M
Free Cash Flow21.84M
Free Cash Flow per Share0.17
Dividends & Yields
Cytek Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.45
52-Week Price Change-59.19%
50-Day Moving Average3.61
200-Day Moving Average5.13
Relative Strength Index (RSI)21.83
Average Volume (3m)818.50K
Important Dates
Cytek Biosciences upcoming earnings date is Aug 12, 2025, TBA Not Confirmed.
Last Earnings DateMay 8, 2025
Next Earnings DateAug 12, 2025
Ex-Dividend Date―
Financial Position
Cytek Biosciences as a current ratio of 5.86, with Debt / Equity ratio of 4.30%
Current Ratio5.86
Quick Ratio5.21
Debt to Market Cap<0.01
Net Debt to EBITDA8.14
Interest Coverage Ratio-3.92
Taxes
In the past 12 months, Cytek Biosciences has paid 320.00K in taxes.
Income Tax320.00K
Effective Tax Rate-0.06
Enterprise Valuation
Cytek Biosciences EV to EBITDA ratio is -76.34, with an EV/FCF ratio of 35.05.
EV to Sales3.82
EV to EBITDA-76.34
EV to Free Cash Flow35.05
EV to Operating Cash Flow30.18
Balance Sheet
Cytek Biosciences has $277.86M in cash and marketable securities with $17.02M in debt, giving a net cash position of -$260.85M billion.
Cash & Marketable Securities$277.86M
Total Debt$17.02M
Net Cash-$260.85M
Net Cash Per Share-$2.06
Tangible Book Value Per Share$2.75
Margins
Gross margin is 55.43%, with operating margin of -10.24%, and net profit margin of -3.00%.
Gross Margin55.43%
Operating Margin-10.24%
Pretax Margin-2.84%
Net Profit Margin-3.00%
EBITDA Margin-5.01%
EBIT Margin-10.24%
Analyst Forecast
The average price target for Cytek Biosciences is $5.90, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$5.90
Price Target Upside143.80% Upside
Analyst ConsensusHold
Analyst Count5
Revenue Growth Forecast-1.86%
EPS Growth Forecast-2.01%